Daxor (NASDAQ:DXR) PT Raised to $24.75 at Ascendiant Capital Markets

Daxor (NASDAQ:DXR) had its target price hoisted by stock analysts at Ascendiant Capital Markets from $24.50 to $24.75 in a report released on Monday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price objective points to a potential upside of 162.46% from the stock’s previous close.

Daxor Trading Up 4.7 %

Shares of DXR stock opened at $9.43 on Monday. Daxor has a 12 month low of $7.11 and a 12 month high of $10.04. The stock has a 50 day moving average of $8.83 and a two-hundred day moving average of $8.95.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.